首页> 外文OA文献 >Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

【2h】

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

机译：FLT3激酶抑制剂中豚鼠的IP相IB研究中小期新诊断的成年患者急性髓白血病

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
R M Stone; T Fischer; R Paquette; G Schiller; C A Schiffer; G Ehninger; J Cortes; H M Kantarjian; D J DeAngelo; A Huntsman-Labed; C Dutreix; A del Corral; F Giles;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Midostaurin in Adults with Newly Diagnosed FLT3-Mutation-Positive Acute Myeloid Leukemia Eligible for Standard Chemotherapy: Update from the Radius-X Midostaurin Expanded Access Program [J] . Perl Alexander E., Sweet Kendra L., Roboz Gail J., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：中豚在成人患有新诊断的FLT3-突变阳性急性骨髓白血病符合标准化疗的条件：从RADIUS-X MIDOSTAURIN扩展访问程序的更新
2. Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy [J] . Voso Maria Teresa, Larson Richard A., Prior Thomas, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：批准（联盟10603）：用中毒素或安慰剂治疗新诊断急性髓性白血病（AML）患者FLT3酪氨酸激酶结构域（TKD）和NPM1突变状态的预后抗病症
3. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation–Positive Acute Myeloid Leukemia [J] . Miryoung Kim, Sherry Williams The annals of pharmacotherapy . 2018,第4期

机译：中豚与标准化疗组合治疗新诊断的FMS样酪氨酸激酶3（FLT3）突变阳性急性髓性白血病
4. Tandem mass spectrometry characterizes the related substances of second generation FLT3 inhibitor Quizartinib, anti cancer compound for myeloid leukemia [C] . Saravanan Subramaniyan, Arvind Thyagarajan, Rampriya Uthayakumar, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：串联质谱表征第二代FLT3抑制剂Quizartinib的相关物质，用于髓性白血病的抗癌化合物
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia [O] . Richard M. Stone, Thomas Fischer, Ronald Paquette, -1

机译：FLT3激酶抑制剂中豚鼠的IP相IB研究中小期新诊断的成年患者急性髓白血病
7. Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients [O] . Mehmet BAYSAL, Nihan ALKİS, Serap BAYSAL 2021

机译：新诊断术急性髓性白血病患者FLT3抑制剂中豚（FLT3抑制剂）体验

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

著录项

引文网络

相似文献

相关主题

期刊订阅